Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8987223
APP PUB NO 20120294846A1
SERIAL NO

13470780

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ONCOGENEX TECHNOLOGIES INC400-1001 W BROADWAY VANCOUVER BRITISH COLUMBIA V6H 4B1

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bonniaud, Philippe Dijon, FR 2 1
Garrido, Carmen Talant, FR 5 1
Wettstein, Guillaume Dijon, FR 4 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 24, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00